에 대한 최신 뉴스 Qifu Technology (NASDAQ:QFIN) 주식

Qifu Technology

360 DigiTech

Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.

ASTSpaceMobile.Screenshotvideo

Mid Cap

News

Movers

Trading Ideas

ASTS

INTA

LITE

LOAR

QFIN

RKLB

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? AST 스페이스모바일(NASDAQ:ASTS)의 주가는 회사가 9월 초 위성 5개를 발사할 예정이라고 발표한 후 48.26% 급등했다. 

AST 스페이스모바일 및 로켓랩은 지난주 최고 성과를 보여준 7개 중형주 중 일부 (8월 11일-8월 17일)

Qifu Technology, Inc - American Depositary Shares

Qifu Technology Inc

WIIM

SPOT

Spotify Technology shares are trading higher after JP Morgan raised its price target on the stock from $670 to $730.

GTLS

Flowserve and Chart Industries shares are trading lower after the two companies announced they will engage in a $19 billion merger.

<a href="https://www.barrons.com/articles/on-semiconductor-chip-stock-price-755e718a?mod=md_stockoverview_news">https://www.barrons.com/articles/on-semiconductor-chip-stock-price-755e718a?mod=md_stockoverview_news</a>

General

'ON Semiconductor Stock Rises. CEO Says the Chip Maker's Worst Days Are Over.'- Barrons

WING

Wingstop shares are trading higher after Goldman Sachs raised its price target on the stock from $310 to $390.

Centrus Energy shares are trading higher after B of A Securities initiated coverage on the stock with a Buy rating and announced a price target of $160.

On Tuesday, Zydus Lifesciences Ltd. announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) U.S.-based <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45743601/zydus-to-enter-global-biologics-cdmo-business-plans-to-acquire-agenus-u-s-manufacturing-facilities" rel="noreferrer noopener">biologics CMC facilities</a>.
The acquisition marks Zydus&#8217; strategic investment in U.S.-based biologics manufacturing, thereby adding a sustainable growth driver for the group.
Agenus is a clinical-stage <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">immuno-oncology company</a>.
Zydus will acquire two biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California, for an upfront consideration of $75 million and a contingent payment of $50 million to be paid over three years subject to the achievement of certain revenue milestones.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42216436/agenus-secures-22m-mortgage-and-announces-strategic-realignment-to-focus-on-cancer-drug-development" rel="noreferrer noopener">Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development</a>
This acquisition provides Zydus with immediate access to advanced biologics manufacturing capabilities and establishes a key presence in&nbsp;California.
As part of the transaction, Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for the clinical and commercial supply of two identified Phase-3-ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL).
Zydus will also have the first right of negotiation to manufacture any of the future pipeline products developed by Agenus. Zydus intends to further expand the team.
The company presented new translational data for BOT/BAL at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The study demonstrated that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC).
HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;We are unsurprised by the manufacturing facilities&#8217; sale and outlicensing of bot/bal as these decisions were consistent with remarks previously made by management.&#8221;
During its first-quarter earnings, Agenus said it is on track to reduce its annualized operating cash burn below $50 million starting in the second half of 2025, supported by recent cost optimization measures enabling the company to direct resources toward realizing the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45344207/agenus-reports-q1-2025-financial-results-and-key-business-updates" rel="noreferrer noopener">potential of BOT/BAL</a>.
The company also mentioned it is in the final stages of an important collaboration, which will result in a substantial cash infusion.
Agenus ended the first quarter of 2025 with a consolidated cash balance of $18.5 million.
The analyst says the company has sufficient funding to advance bot/bal through a Phase 3 trial, which is expected to be initiated in the second half of 2025.
Bodnar upgraded the stock from Neutral to Buy, with <a href="https://www.benzinga.com/quote/AGEN/analyst-ratings" target="_blank" rel="noreferrer noopener">a price target of $25</a>.
The analyst estimates bot/bal approval in the U.S. and EU in 2028 and 2029, respectively, with peak market penetrations of 30% in the U.S. by 2034 and 15% in the EU by 2035.
HC Wainwright estimates peak sales for bot/bal in third-line MSS-CRC of ~$929 million by 2038.
Baird maintains Agenus with a Neutral, raising the price target from $4 to $6.
Price Action: AGEN stock is up 17% at $5.86 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45768838/rivian-evs-just-got-smarter-new-app-tracks-energy-use-and-speeds-up-charging" target="_blank" rel="noreferrer noopener">Rivian EVs Just Got Smarter: New App Tracks Energy Use And Speeds Up Charging</a></li>
</ul>
Photo: Gorodenkoff/Shutterstock

Biotech

Upgrades

Health Care

Contracts

Analyst Ratings

AGEN

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Chagee Holdings shares are trading higher after Citigroup initiated coverage on the stock with a Buy rating and announced a price target of $43.7.

Macquarie analyst Steve Koenig maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Neutral and raises the price target from $190 to $210.

Price Target

SNOW

Macquarie Maintains Neutral on Snowflake, Raises Price Target to $210

APLD

Applied Digital shares are trading higher after B. Riley Securities raised its price target on the stock from $8 to $15.

ACLS

ALAR

ALGM

AMBA

AMKR

AOSL

AVGO

BZAI

CEVA

CRDO

DIOD

ENTG

KLIC

MCHP

MKSI

MOBX

MPWR

NVDA

NVTS

NXPI

OLED

QCOM

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

WOLF

Shares of several semiconductor companies are trading higher amid GlobalFoundries' announcement to commit $16 billion towards US chip expansion, which may be buoying investor sentiment towards the space.

JP Morgan analyst Mark R Murphy <a href="https://www.benzinga.com/quote/DOCU/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained a Neutral rating</a> on DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a price forecast of $81 on Tuesday.
Heading into DocuSign&#8217;s fiscal first-quarter earnings report, Murphy maintained a cautiously optimistic view, expecting the company to deliver relatively stable execution despite a dynamic-but-manageable macro environment.
The analyst noted that DocuSign&#8217;s recent pattern of fairly conservative guidance sets the company up well to deliver upside to current fiscal first-quarter estimates, while still likely allowing it to maintain some cushion for the back-half of the year to account for ongoing macroeconomic and geopolitical volatility.
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45776761/jpmorgan-bullish-on-hewlett-packard-enterprises-future-cites-durable-non-ai-segments-capital-returns">JPMorgan Bullish On Hewlett Packard Enterprise&#8217;s Future, Cites &#8216;Durable&#8217; Non-AI Segments, Capital Returns</a>
He continues to sense a more balanced risk-reward profile for DocuSign in the medium term, with Intelligent Agreement Management (IAM) traction continuing to drive some stabilization and improvement in growth rates. This is partially balanced by an inferior GAAP profitability framework amid an ongoing IAM investment cycle and some exposure to macro-sensitive end-markets.
Murphy noted that DocuSign is well positioned to meet or exceed its fiscal first-quarter guidance bar, calling for +6% CC revenue and proforma billings growth. Both of these call for some deceleration versus the prior quarter, though they include some leap year impact.
While DocuSign may elect not to entirely pass through any fiscal first-quarter upside nor incremental currency favorability to the full-year guidance, similar to peers, the analyst noted this could create a favorable setup for the second half, particularly as IAM contributions continue to feather in. Partially balancing this, Murphy said that DocuSign&#8217;s fiscal 2026 outlook assumes consistent macro trends relative to when it was provided in mid-March. As a result, any degradation in underlying demand activity could exert some drag against ongoing improvements in the core business and go-to-market efforts.
While the analyst noted the potential for some continued variability in key metrics, such as customer adds and DNR, he continued to monitor for commentary related to envelopes sent and consumption, for which the company&#8217;s indications have been encouraging in recent quarters, to assess the underlying health of the core business, including in more macro-volatile verticals and geographies. In addition, coming off DocuSign Momentum, where the company highlighted new AI-driven products such as AI Contract Agents backed by its Iris AI engine, Murphy remains focused on DocuSign&#8217;s ability to drive further upsell and diversification from its core eSign base through newer features, likely to aid retention trends over time.
As a reminder, DocuSign also commented that it expects this IAM contribution to grow in fiscal 2026 and represent a &#8220;low-double-digit&#8221; percentage share of its total subscription recurring book of business (ARR) by the fiscal fourth quarter.
Overall, Murphy remains encouraged by the pacing of adoption for this broader IAM platform, which has aligned with his view of an accelerated adoption cycle relative to contract lifecycle management (CLM). 
He noted that much of the penetration today has been in the small and mid-market segments, with the enterprise segment and self-serve motion likely to ramp gradually as the year progresses.
As a reminder, DocuSign disclosed at its Momentum conference in April that over 10K customers had purchased IAM.
The analyst noted that IAM adoption by a &#8220;low-double-digit&#8221; share of the total Subs ARR base by year-end could drive a fairly meaningful uplift in the spending of existing eSign users, potentially resulting in a low-single-digit tailwind to growth trends in the medium-term.
Overall, Murphy noted this as a fairly tepid reading on balance when evaluated on a Y/Y growth basis, though he noted that these results for the first quarter land above five of the past ten quarters.
While an informative additional data point, he cautioned investors from over-indexing these web traffic figures, given the volatility in these metrics and an absence of supporting transaction-based trends within this data.
Murphy projected first-quarter revenue of $747 million and adjusted EPS of $0.82.
Price Action: DOCU stock is trading higher by 1.10% to $92.62 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45756083/which-internet-software-stocks-is-jp-morgan-bullish-on" target="_blank" rel="noreferrer noopener">Which Internet Software Stocks Is JP Morgan Bullish On?</a></li>
</ul>
Image via Shutterstock

Reiteration

DOCU

DocuSign Macro Risks Could Cap Upside Despite AI, IAM Traction: Analyst

TD Securities analyst Aaron Bilkoski maintains Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) with a Buy and raises the price target from $57 to $58.

VNOM

TD Securities Maintains Buy on Viper Energy, Raises Price Target to $58

TD Securities analyst Sean Steuart maintains Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) with a Hold and raises the price target from $6 to $6.5.

TD Securities Maintains Hold on Algonquin Power, Raises Price Target to $6.5

Guidance

VSCO

CORRECTION: Victoria's Secret & Co Sees Q1 2025 Net Sales Of $1.35B Vs $1.42B Estimate; Adj. EPS Of $0.09 Vs $0.04 Estimate

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continues to hover near key resistance, with traders closely watching support levels to avoid a <a href="http://deeper summer correction">deeper summer correction</a>.
What Happened: In an update in his <a href="https://www.patreon.com/c/KevCapitalTA/posts">exclusive Patreon group</a>, prominent analyst Kevin highlighted that BTC has once again failed to break above the $106,800 resistance, a level that aligns with the macro 1.703 Fibonacci extension. 
After a 50% rally from cycle lows without a significant pullback, rejection at this level was anticipated.
Kevin pointed to recent golden crosses on both the daily and weekly timeframes (50/200 SMA and 21 EMA/20 SMA), typically followed by 7–10% corrections, and occasionally deeper ones. 
A fresh weekly hash ribbon buy signal—a historically reliable bullish indicator, has also flashed but often precedes short-term dips before upside continuation.
Despite bullish technical setups, Kevin noted mixed macro conditions and seasonal weakness in crypto markets. 
If Bitcoin fails to hold support between $100,000–$103,000, it could slide into a prolonged correction. 
If support holds, BTC could finally break through $106,800 and resume its upward trend.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45772932/bitcoins-post-golden-cross-correction-playing-out-benjamin-cowen-flags-signs-of-q3-weakness">Bitcoin&#8217;s Post-Golden Cross Correction Playing Out — Benjamin Cowen Flags Signs Of Q3 Weakness</a>
Why It Matters: Daan Crypto Trades <a href="https://x.com/DaanCrypto/status/1930293971370291252">echoed</a> the uncertain near-term outlook, emphasizing that Bitcoin&#8217;s price has reliably followed a 4-year halving cycle, whether measured top-to-top or bottom-to-bottom.
He pushed back against speculation that this cycle will behave differently due to ETFs or broader market maturity, arguing that such claims were made in prior cycles too. 
"Skepticism about the cycle actually strengthens it," he said, reaffirming his plan to scale out of positions gradually through late 2025, just as he did in the 2021 cycle peak.
What's Next: Traders now look to the $100,000–$103,000 zone as a critical line in the sand. 
A breakdown could open the door to a summer slump, while a rebound might trigger a breakout above resistance, potentially setting the stage for a fresh leg up.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45767169/bitcoin-ethereum-xrp-dogecoin-tick-up-as-battle-for-105000-intensifies">Bitcoin, Ethereum, XRP, Dogecoin Tick Up As &#8216;Battle For $105,000&#8217; Intensifies</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Stuck At $105,000: What Does Technical Analysis Say?

SSRM

SSR Mining shares are trading lower after the company announced its operations at Seabee have been temporarily suspended.

AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rheumatoid arthritis</a>.
In the 424-patient 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45757627/anaptys-announces-positive-rosnilimab-data-updated-through-six-months-in-robust-phase-2b-trial-in-" rel="noreferrer noopener">over six months</a>.
Furthermore, responses were then durable for at least two months off the drug.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42445688/anaptysbio-discontinues-investment-in-eczema-candidate-after-disappointing-data" rel="noreferrer noopener">AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data</a>
Rosnilimab was safe and well tolerated, particularly compared to standard-of-care biologics or JAKs.
All three doses (100mg Q4W, 400mg Q4W, 600mg Q2W) achieved statistically significant reductions in DAS-28 CRP and ACR20 at Week 12 versus placebo.
CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses by Week 14.
The company aims to complete its Phase 2 study for rosnilimab in ulcerative colitis/UC, with initial data expected in the fourth quarter of 2025.
As of the March 11, 2025&nbsp;data cutoff date, 83% were still in LDA at Week 34 across all doses. Of the remaining 17% of patients who did not sustain CDAI LDA at Week 34, most remained near the cutoff of CDAI=10, with a median CDAI of 13.
Rosnilimab demonstrated clinically meaningful improvements that deepened through Week 28 across multiple validated patient-reported outcomes, including the pain visual analog scale (VAS) and the health assessment questionnaire, or HAQ-Disability Index (DI), a self-reporting tool to measure function and disability.
HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;Given the data showcase a positive holistic story for rosnilimab in RA, we are increasingly positive on upcoming UC data.&#8221;
Bodnar upgraded AnaptysBio from Neutral to Buy, raising the price target<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings" target="_blank" rel="noreferrer noopener"> from $22 to $38</a>.
HC Wainwright Highlights Competitor Datasets
Data using non-responder imputation (NRI) from Week 24 of the SELECT-CHOICE trial, which compared AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Rinvoq vs Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Orencia in rheumatoid arthritis (RA), showed similar results for both drugs. These findings align with the results seen for the company&#8217;s rosnilimab at Week 28, even though about 29% of patients had previously been treated with JAK inhibitors.
In contrast, Eli Lilly And Co&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) now-discontinued PD-1 agonist peresolimab showed a drop in CDAI LDA rates—from 55% at Week 14 to 37% at Week 24. This is notably lower than the 53–63% range reported for rosnilimab at Week 28.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is also set to present early data for its PD-1 agonist at the upcoming EULAR conference, though its study is smaller than AnaptysBio&#8217;s.
Price Action: ANAB stock is down 12.1% at $20.66 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45769045/tariffs-ai-and-trade-war-apples-smartphone-growth-to-take-a-hit-experts-say" target="_blank" rel="noreferrer noopener">Tariffs, AI And Trade War: Apple&#8217;s Smartphone Growth To Take A Hit, Experts Say</a></li>
</ul>
Photo: Shutterstock

Analyst Color

ABBV

ANAB

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Peloton Interactive, Inc. shares are trading higher Wednesday. On Tuesday, a report suggested the company is launching a resale market for used bikes and treadmills.
The Details: According to <a href="https://www.cnbc.com/2025/06/03/peloton-launching-resale-market-for-used-bikes-treadmills.html">CNBC</a>, Peloton has rolled out Repowered, a platform that lets users list their used equipment and apparel, with pricing guidance provided by a generative artificial intelligence tool.
Sellers will receive 70% of the sale price, with the remainder shared between Peloton and its resale partner Archive. They will also get a discount toward new equipment. Buyers will benefit from a lower activation fee, which the company said is dropping from $95 to $45 for used products. 
Peloton said buyers will be able to view the equipment's history on the listing and can choose to have it delivered for an additional fee.
The company also said that as of last summer, connected fitness subscriptions from customers who purchased hardware through secondary channels were up 16% year-over-year.
Repowered launched as a beta version in New York City, Boston and Washington D.C., with plans to expand across the United States in the coming months.
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45776761/jpmorgan-bullish-on-hewlett-packard-enterprises-future-cites-durable-non-ai-segments-capital-returns">JPMorgan Bullish On Hewlett Packard Enterprise&#8217;s Future, Cites &#8216;Durable&#8217; Non-AI Segments, Capital Returns</a>
PTON Price Action: At the time of writing, Peloton shares are trading 11.2% higher at $7.40, according to data from Benzinga Pro.
Image: via Shutterstock

PTON

Peloton Stock Is Climbing Higher Wednesday: What's Going On?

<a href="https://www.wsj.com/business/media/meta-seeks-hollywood-deals-for-new-virtual-reality-headset-ef3db942">https://www.wsj.com/business/media/meta-seeks-hollywood-deals-for-new-virtual-reality-headset-ef3db942</a>

'Meta Seeks Hollywood Deals for New Virtual-Reality Headset'- WSJ

Wells Fargo &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) shares are trading higher Wednesday following its announcement that it&#8217;s no longer subject to asset growth restrictions that were <a href="https://www.benzinga.com//node/45758069">imposed in 2018</a>.
What To Know: On Tuesday, Wells Fargo said the Federal Reserve lifted the asset cap that had been in place since 2018, a penalty tied to the bank's fake-account scandal, according to the <a href="https://apnews.com/article/wells-fargo-federal-reserve-sales-practices-assets-e1d79548c0da446320c441e88de3eea4">Associated Press</a>.
The Federal Reserve&#8217;s decision to lift the asset cap marks a pivotal milestone in our journey to transform Wells Fargo. We are a different and far stronger company today because of the work we&#8217;ve done,&#8221; said Wells Fargo CEO Charlie Scharf.&nbsp;
The fake-accounts scandal, which erupted in 2018, stemmed from a high-pressure sales culture that led employees to open millions of unauthorized accounts in an effort to meet aggressive performance goals.
Since taking the helm in 2019, Scharf has worked to convince regulators that Wells Fargo has overhauled its practices and addressed longstanding compliance failures.
&#8220;In addition, we have changed and simplified our business mix, and we have transformed the management team and how we run the company. We have been methodically investing in the company&#8217;s future while improving our financial results and profile,&#8221; Scharf added.
&#8220;We are excited to continue to move forward with plans to further increase returns and growth in a deliberate manner supported by the processes and cultural changes we have made.&#8221;
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45775027/pump-funs-1b-token-plan-risks-undermining-solana-defi-fueling-meme-coin-scams-experts-warn">Pump.fun&#8217;s $1B Token Plan Risks Undermining Solana DeFi, Fueling Meme Coin Scams, Experts Warn</a>
WFC Price Action: At the time of publication, Wells Fargo stock is trading 0.41% higher at $75.96, according to data from <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/pro/&amp;ved=2ahUKEwjk9-eNmtiNAxWxg4kEHSKNIm4QFnoECAoQAQ&amp;usg=AOvVaw0xIsPvjIcIIsWev01-6zR2">Benzinga Pro</a>.
Image: via Shutterstock

Wells Fargo Stock Is Trading Higher Wednesday: What's Going On?

Press Releases

Qifu Technology, Inc. Announces Proposed Offering of US$600 Million Cash-par Settled Convertible Senior Notes

Qifu Technology Filed 2024 Annual Report on Form 20-F

Qifu Technology Releases 2024 ESG Report

Markets

Qifu Technology, Inc. Announces Pricing of Offering of US$600 Million Cash-par Settled Convertible Senior Notes

Qifu Technology, Inc. Announces Completion of Offering of US$690 Million Cash-par Settled Convertible Senior Notes

Qifu Technology to Announce First Quarter 2025 Unaudited Financial Results on May 19, 2025

Fintech

Qifu Technology's Paper Accepted by IJCAI 2025, Using MLLM to Pave New Path in Fintech

Qifu Technology to Hold Annual General Meeting on June 30, 2025

Earnings

Qifu Technology Announces First Quarter 2025 Unaudited Financial Results

Qifu Technology Won the Title of "MOST HONORED COMPANY" for the Second Consecutive Year

Ally Financial

American Express

Bread Financial Holdings, Inc. Common Stock

Bread Finl Hldgs

Credit Acceptance Corporation - Common Stock

Credit Acceptance

Capital One Financial Corporation Common Stock

Capital One Finl

Dave

Encore Capital Gr

Enova International

EZCORP, Inc. - Class A Non-Voting Common Stock

EZCORP

FirstCash Hldgs

FinVolution Group American Depositary Shares

FinVolution Group

Jiayin Group Inc. - American Depositary Shares

Jiayin Gr

Joint Stock Company Kaspi.kz - American Depository Shares

Kaspi.kz

LendingClub

Lufax Holding Ltd American Depositary Shares, each representing two (2) Ordinary Shares

Lufax Holding

LexinFintech Holdings Ltd. - American Depositary Shares

LexinFintech Holdings

Navient

Nelnet

OneMain Holdings

PROG Holdings

SoFi Technologies

Synchrony Financial

Upstart Hldgs

World Acceptance Corporation - Common Stock

World Acceptance

B of A Securities

Citigroup

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>AST 스페이스모바일(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/40398813" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">9월 초 위성 5개</a>를 발사할 예정이라고 발표한 후 48.26% 급등했다. </li>
<li>템푸스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>)의 주식은 30.93% 뛰었다.</li>
<li>인탭(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTA#NASDAQ">INTA</a>)의 주가는 회사가 양호한 <a href="https://www.benzinga.com//node/40350753" target="_blank" rel="noreferrer noopener">4분기 실적</a>을 발표하고 가이던스를 발표한 이후 27.59% 상승했다. 많은 분석가들이 회사의 가격 <a href="https://www.benzinga.com/quote/inta/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>로어 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>)의 주가는 이 회사가 예상을 웃도는 <a href="https://www.benzinga.com//node/40335395" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 GAAP 순이익과 매출</a>을 발표한 후 25.28% 급등했다.</li>
<li>로켓랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)의 주가는 회사가 발사 준비를 위해 화성행 우주선 두 대를 플로리다주 케이프커내버럴로 배송한 후 21.03% 상승했다.</li>
<li>치푸 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>)의 주가는 2분기 재무 결과를 발표한 뒤 지난주 19.98% 급등했다.</li>
<li>루멘텀 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>)의 주식은 이 회사가 <a href="https://www.benzinga.com//node/40395893" target="_blank" rel="noreferrer noopener">강한 4분기 실적을 보고한 뒤 </a>19.44% 상승했다. 이에 따라 이 회사의 주가에 대한 <a href="https://www.benzinga.com//node/40395893" target="_blank" rel="noreferrer noopener">애널리스트들의 주가 예측이</a> 높아졌다.</li>
</ol>
한편 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%97%94%eb%b9%84%eb%94%94%ec%95%84-%ec%8a%a4%ed%83%80%eb%b2%85%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac/" target="_blank" rel="noopener">엔비디아, 스타벅스 및 델은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 11일-8월 17일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%ec%b9%98%ed%8f%b4%eb%a0%88%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c-%eb%8c%80/" target="_blank" rel="noopener">리비안과 치폴레는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 11일-8월 17일)</a></li>
</ul>
AST SpaceMobile를 통한 사진






Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Qifu Technology

뉴스

에 대한 최신 뉴스 Qifu Technology (NASDAQ:QFIN) 주식

일요일, 8월 18, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌